Dr. Erica Schwartz Confirmed as CDC Director Amidst Deep-Seated Challenges and Public Health Turmoil
admin Dr. Erica Schwartz has been confirmed as the next director of the Centers for Disease...
Biotech, Pharma & Cancer Drug Development
Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals in Up to $800 Million Deal, Advancing Stargardt Disease Treatment
Tarsus Pharmaceuticals, a prominent developer of treatments across ophthalmology, dermatology, and infectious diseases, has announced...
FDA Grants Accelerated Approval to Replimune’s Tudriqev for Advanced Melanoma After Contentious Review Process
The U.S. Food and Drug Administration (FDA) has officially granted accelerated approval to Replimune’s novel...
FDA Approves Orzeyful, a Groundbreaking Orexin-2 Agonist, Ushering in a New Era for Narcolepsy Type 1 Treatment
The U.S. Food and Drug Administration (FDA) has granted approval to Orzeyful, a novel medicine...
FDA Approves Moderna’s mFlusiva, Marking a Landmark Entry for mRNA Technology into Seasonal Flu Vaccination
The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, previously known as...
Braveheart Bio Spearheads Biotech IPO Surge, As Five Firms Secure Over $1 Billion in Public Offerings This Week
Braveheart Bio, a rapidly emerging biotechnology company focused on cardiovascular therapies, has successfully completed its...
Novo Nordisk Faces Setbacks as Eli Lilly’s Injectable Franchise Continues to Outperform in Fierce GLP-1 Market
The intense rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly in the burgeoning market...
Attovia Therapeutics Secures $289 Million in Upsized IPO, Signifying Robust Biotech Market Recovery
Attovia Therapeutics, a burgeoning biotechnology firm focused on innovative antibody-drug technologies for skin disorders and...
Expedition Therapeutics Secures $115 Million Series B to Advance Novel Lung Disease Therapy, Reinforcing Trend of China-Originated Drug Development
Expedition Therapeutics, a rapidly emerging biotechnology company focused on bringing innovative therapies to market, announced...
Biopharmaceutical Sector Witnesses Executive Transition at J&J, Mixed Clinical Outcomes, Strategic Alliances, and Expanded Drug Approvals
The biopharmaceutical landscape has recently been marked by a series of significant developments, including a...
